Targets › ICOS
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Stimulatory receptor expressed in activated or antigen-experienced T-cells that plays an important role in the immune response. Upon binding to its ligand ICOSL expressed on antigen presenting cells (APCs), delivers costimulatory signals that enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines including IL10, up-regulation of molecules that mediate cell-cell…. (UniProt, Q9Y6W8)
Open in Phaseline: the race on ICOS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Anti-ICOS Monoclonal Antibody MEDI-570 anti-ICOS monoclonal antibody | ICOS | Phase 1 | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Dec 2026 |
| GSK | Feladilimab Inducible T-cell costimulator agonist | ICOS | Phase 1 | Multiple Myeloma | Mar 2027 |
Multiple Myeloma (2) Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (1)
mixed (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.